Top

Published in:

01-03-2018 | Commentary

Employer’s management of employees affected by cancer

Authors: Z. Amir, A. Popa, S. Tamminga, D. Yagil, F. Munir, A. de Boer

Published in: Supportive Care in Cancer | Issue 3/2018

Excerpt

Return to work (RTW) following treatment can be problematic for cancer survivors. Although some people affected by cancer are able to continue working, a greater proportion of these survivors end up unemployed, retire early or change jobs than those without a diagnosis of cancer [1]. One of the reasons for not returning to work is the lack of understanding and support from employers and supervisors [2]. Currently, it is not clear what factors are likely to influence the employer’s management of employees recovering from cancer. This article reports the outcome from a review of the published literature on factors related to the current employer management of employed cancer survivors. …

De Boer AG, Taskila T, Ojajärvi A, van Dijk FJ, Verbeek JH (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301(7):753–762. https://doi.org/10.1001/jama.2009.187 CrossRefPubMed

Tiedtke C, Dierckx de Casterlé B, Donceel P, de Rijk A (2015) Workplace support after breast cancer treatment: recognition of vulnerability. Disabil Rehabil 37(19):1770–1776. https://doi.org/10.3109/09638288.2014.982830 CrossRefPubMed

National Institute for Health and Care Excellence (NICE) (2012). Methods for the development of NICE public health guidance (third edition). Accessed from: http://publications.nice.org.uk/methods-for-the-development-of-nice-public-health-guidance-third-edition-pmg4/determining-the-evidence-for-review-and-consideration#CPHE-correlates-reviews)

de Rijk A, van Raak A, van der Made J (2007) A new theoretical model for cooperation in public health settings: the RDIC model. Qual Health Res 17(8):1103–1116. https://doi.org/10.1177/1049732307308236 CrossRefPubMed

Amir Z, Neary D, Luker K (2008) Cancer survivors’ views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs 12(3):190–197. https://doi.org/10.1016/j.ejon.2008.01.006 CrossRefPubMed

Amir Z, Wynn P, Whitaker S, Luker K (2009) Cancer survivorship and return to work: UK occupational physician experience. Occup Med 59(6):390–396. https://doi.org/10.1093/occmed/kqn150 CrossRef

Amir Z, Wynn P, Chan F, Strauser D, Whitaker S, Luker K (2010) Return to work after cancer in the UK: attitudes and experiences of line managers. J Occup Rehabil 20(4):435–442. https://doi.org/10.1007/s10926-009-9197-9 CrossRefPubMed

Ashing-Giwa KT, Padilla G, Tejero J, Kraemer J, Wright K, Coscarelli A, Hills D (2004) Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors. Psycho-Oncology 13(6):408–428. https://doi.org/10.1002/pon.750 CrossRefPubMedPubMedCentral

Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Mazumdar M (2012) Employment after a breast cancer diagnosis: a qualitative study of ethnically diverse urban women. J Community Health 37(4):763–772. https://doi.org/10.1007/s10900-011-9509-9 CrossRefPubMed

10.

Eguchi H, Wada K, Higuchi Y, Smith DR (2017) Co-worker perceptions of return-to-work opportunities for Japanese cancer survivors. Psycho-Oncology 26(3):309–315. https://doi.org/10.1002/pon.4130 CrossRefPubMed

11.

Ehrmann-Feldmann D, Spitzer WO, Del Greco L, Desmeules L (1987) Perceived discrimination against cured cancer patients in the work force. CMAJ: Can Med Assoc J 136(7):719–723

12.

Grunfeld EA, Low E, Cooper AF (2010) Cancer survivors’ and employers’ perceptions of working following cancer treatment. Occup Med 60(8):611–617. https://doi.org/10.1093/occmed/kqq143 CrossRef

13.

Lindbohm ML, Taskila T, Kuosma E, Hietanen P, Carlsen K, Gudbergsson S, Gunnarsdottir H (2012) Work ability of survivors of breast, prostate, and testicular cancer in Nordic countries: a NOCWO study. J Cancer Surviv 6(1):72–81. https://doi.org/10.1007/s11764-011-0200-z CrossRefPubMed

14.

Luker K, Campbell M, Amir Z, Davies L (2013) A UK survey of the impact of cancer on employment. Occup Med 63(7):494–500. https://doi.org/10.1093/occmed/kqt104 CrossRef

15.

Main CJ, Shaw WS (2016) Employer policies and practices to manage and prevent disability: conclusion to the special issue. J Occup Rehabil 26(4):490–498. https://doi.org/10.1007/s10926-016-9655-0 CrossRefPubMedPubMedCentral

16.

Mak AKY, Chaidaroon S, Fan G, Thalib F (2014) Unintended consequences: the social context of cancer survivors and work. J Cancer Surviv 8(2):269–281. https://doi.org/10.1007/s11764-013-0330-6 CrossRefPubMed

17.

Mak AKY, Ho SS, Kim HJ (2014) Factors related to employers’ intent to hire, retain and accommodate cancer survivors: the Singapore perspective. J Occup Rehabil 24(4):725–731. https://doi.org/10.1007/s10926-014-9503-z CrossRefPubMed

18.

McGrath PD, Hartigan B, Holewa H, Skarparis M (2012) Returning to work after treatment for haematological cancer: findings from Australia. Support Care Cancer 20(9):1957–1964. https://doi.org/10.1007/s00520-011-1298-2 CrossRefPubMed

19.

McKay G, Knott V, Delfabbro P (2013) Return to work and cancer: the Australian experience. J Occup Rehabil 23(1):93–105. https://doi.org/10.1007/s10926-012-9386-9 CrossRefPubMed

20.

Poulsen MG, Khan A, Poulsen EE, Khan SR, Poulsen AA (2016) Work engagement in cancer care: the power of co-worker and supervisor support. Eur J Oncol Nurs 21(21):134–138. https://doi.org/10.1016/j.ejon.2015.09.003 CrossRefPubMed

21.

Pransky GS, Fassier JB, Besen E, Blanck P, Ekberg K, Feuerstein M, Hopkinton Conference Working Group on Workplace Disability, P (2016) Sustaining work participation across the life course. J Occup Rehabil 26(4):465–479CrossRefPubMedPubMedCentral

22.

Selander J, Tjulin Å, Müssener U, Ekberg K (2015) Contact with the workplace during long-term sickness absence and worker expectations of return to work. Int J Disability Manag Res 10:13. https://doi.org/10.1017/idm.2015.3

23.

Stergiou-Kita M, Pritlove C, Kirsh B (2016) The “Big C”-stigma, cancer, and workplace discrimination. J Cancer Surviv 10(6):1035–1050. https://doi.org/10.1007/s11764-016-0547-2 CrossRefPubMed

24.

Stergiou-Kita M, Pritlove C, van Eerd D, Holness LD, Kirsh B, Duncan A, Jones J (2016) The provision of workplace accommodations following cancer: survivor, provider, and employer perspectives. J Cancer Surviv 10(3):489–504. https://doi.org/10.1007/s11764-015-0492-5 CrossRefPubMed

25.

Stewart DE, Cheung AM, Duff S, Wong F, McQuestion M, Cheng T, Bunston T (2001) Long-term breast cancer survivors: confidentiality, disclosure, effects on work and insurance. Psycho-Oncology 10(3):259–263. https://doi.org/10.1002/pon.499 CrossRefPubMed

26.

Tan FL, Loh SY, Su T, Veloo VW, Ng LL (2012) Return to work in multi-ethnic breast cancer survivors-a qualitative inquiry. Asian Pac J Cancer Prev 13(11):5791–5797. https://doi.org/10.7314/APJCP.2012.13.11.5791 CrossRefPubMed

27.

Tamminga SJ, De Boer AG, Verbeek JH, Frings-Dresen MH (2012) Breast cancer survivors’ views of factors that influence the return-to-work process-a qualitative study. Scand J Work Environ Health 38(2):144–154. https://doi.org/10.5271/sjweh.3199 CrossRefPubMed

28.

Taskila T, Lindbohm ML, Martikainen R, Lehto US, Hakanen J, Hietanen P (2006) Cancer survivors’ received and needed social support from their work place and the occupational health services. Support Care Cancer 14(5):427–435. https://doi.org/10.1007/s00520-005-0005-6 CrossRefPubMed

29.

Tiedtke C, Donceel P, De Rijk A, De Casterlé BD (2014) Return to work following breast cancer treatment: the employers’ side. J Occup Rehabil 24(3):399–409. https://doi.org/10.1007/s10926-013-9465-6 PubMed

30.

Yarker J, Munir F, Bains M, Kalawsky K, Haslam C (2010) The role of communication and support in return to work following cancer-related absence. Psycho-Oncology 19(10):1078–1085. https://doi.org/10.1002/pon.1662 CrossRefPubMed

Title: Employer’s management of employees affected by cancer
Authors: Z. Amir
A. Popa
S. Tamminga
D. Yagil
F. Munir
A. de Boer
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 3/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3998-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Impact of body composition on outcome in patients with early breast cancer

Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre

Integrating referral to community-based cancer information and support services in a hospital setting

Can models of self-management support be adapted across cancer types? A comparison of unmet self-management needs for patients with breast or colorectal cancer

How do treatment aims in the last phase of life relate to hospitalizations and hospital mortality? A mortality follow-back study of Dutch patients with five types of cancer

The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer